grant
Novel gene delivery to modulate the tumor microenvironment and antigen-specific antitumor immunity
Organization METHODIST HOSPITAL RESEARCH INSTITUTELocation HOUSTON, UNITED STATESPosted 1 Jun 2024Deadline 31 May 2029
NIHUS FederalResearch GrantFY2025Abscopal effectAdenoviridaeAdenovirusesAdverse ExperienceAdverse eventAffectAnimalsAntibodiesAntigen PresentationAntigen-Presenting CellsAntigensBenchmarkingBest Practice AnalysisBi-specific antibodiesBifunctional AntibodiesBiodistributionBispecific AntibodiesBlood leukocyteBreast CancerBreast Cancer PatientBreast Tumor PatientCD154 AntigensCD40 LigandCD40-LCancer DetectionCancer TreatmentCancerousCancersCell BodyCell DeathCellsCheckpoint inhibitorClinicalClinical OncologyClinical TrialsCollaborationsCytokine ActivationDNA TherapyDendritic CellsDeoxypyrimidine KinaseDeoxythymidine KinaseDrug PrecursorsFDA approvedFutureGene DeliveryGene ExpressionGene Transfer ClinicalGenesGenetic InterventionHIGM1HSVHSV-TkHSV-Tk GeneHerpes Simplex VirusHerpes Simplex Virus Thymidine Kinase GeneHerpes labialis VirusHumanIMD3ImmuneImmune GlobulinsImmune checkpoint inhibitorImmune mediated therapyImmune memoryImmune responseImmune systemImmunesImmunoglobulinsImmunologic MemoryImmunological MemoryImmunologically Directed TherapyImmunotherapeutic agentImmunotherapyIn SituIn VitroInduction TherapyInflammatoryKineticsLaboratoriesLeukocytesLeukocytes Reticuloendothelial SystemLifeLigandsLymphatic TissueLymphoid TissueLytotoxicityMacrophageMalignant Breast NeoplasmMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMarrow leukocyteMediatingMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorMiceMice MammalsModalityModelingModern ManMurineMusMyeloid-derived suppressor cellsMφNEOADJNeoadjuvantNeoadjuvant TherapyNeoadjuvant TreatmentNeoplasm MetastasisOrganOrthologOrthologous GenePDX modelPatient derived xenograftPatientsPenetrationPhasePhenotypePro-DrugsProdrugsProductionPropertyQOLQuality of lifeRadiationReceptor ProteinRecurrenceRecurrentRegimenResearchSecondary NeoplasmSecondary TumorShapesSimplexvirusSiteT cell infiltrationT-B Cell Activating MoleculeT-Cell gp39 AntigenT-CellsT-LymphocyteTNBCTNF-Related Activation ProteinTechnologyTestingTherapeuticTherapeutic IndexThymidine KinaseToxic effectToxicitiesTrainingTreatment EfficacyTumor AntigensTumor BurdenTumor CellTumor ImmunityTumor LoadTumor Necrosis Factor Ligand Superfamily Member 5Tumor TissueTumor-Associated AntigenTumor-Infiltrating LymphocytesValidationVeiled CellsViralViral VectorWhite Blood CellsWhite CellWorkabscopal activityabscopal responseaccessory cellanamnestic reactionantagonismantagonistanti-canceranti-cancer therapyanti-tumor immunityantitumor immunitybenchmarkbsAbcancer antigenscancer immunitycancer immunologycancer metastasiscancer microenvironmentcancer sub-typescancer subtypescancer therapycancer-directed therapycheck point immunotherapycheck point inhibitor therapycheck point inhibitory therapycheck point therapycheckpoint immunotherapycheckpoint inhibitor therapycheckpoint inhibitory therapycheckpoint therapychemotherapyclinical relevanceclinical translationclinically relevantclinically translatablecostcytokinecytotoxicitydosageexperimentexperimental researchexperimental studyexperimentsgene repair therapygene signaturesgene therapygene-based therapygenetic signaturegenetic therapygenomic therapyhost responsehumanized micehumanized mouseimmune check pointimmune check point inhibitorimmune check point therapyimmune checkpointimmune checkpoint therapyimmune drugsimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapeuticsimmune-based therapiesimmune-based treatmentsimmunecheckpointimmuno therapyimmunogenimmunogenicimmunologic therapeuticsimmunoresponseimmunosuppressive myeloid cellsimmunotherapeuticsimmunotherapy agentimprovedindividuals with breast cancerinduction therapiesinnovateinnovationinnovativeintervention efficacymalignancymalignant breast tumormouse modelmultidisciplinarymurine modelmyeloid suppressor cellsmyeloid-derived suppressive cellsnecrocytosisneoplasm immunologyneoplasm/cancerneoplastic cellneutralizing antibodynew drug targetnew drug treatmentsnew druggable targetnew drugsnew pharmacological therapeuticnew pharmacotherapy targetnew therapeutic targetnew therapeuticsnew therapynew therapy targetnext generation therapeuticsnovelnovel drug targetnovel drug treatmentsnovel druggable targetnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy targetnovel therapeutic targetnovel therapeuticsnovel therapynovel therapy targetpatient derived xenograft modelpatients with breast cancerperson with breast cancerpre-clinicalpreclinicalpreventpreventingprogramsreceptorrecombinant adenovirusrelapse patientsresponsesecondary immune responsestandard of caresuccesssuicide genesuppressive myeloid cellstherapeutic efficacytherapy efficacythymus derived lymphocytetransduction efficiencytriple-negative breast cancertriple-negative invasive breast carcinomatumortumor cell metastasistumor immunologytumor microenvironmenttumor-specific antigenvalidationsviral gene deliverywhite blood cellwhite blood corpuscle
Get Agency plan to apply$29.99/mo · 7-day free trial · pipeline · alerts
or
— or —Get email alerts for similar roles
Description preview
Abstract
Technological advancements have yielded novel drug targets and improved cancer detection,
but transformative innovations in treatment modalities are lacking. Leveraging our team's
expertise in gene therapy, breast cancer, cancer immunology, and breast cancer animal and
patient-derived xenograft models, we propose to use recombinant…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click